regeneron_8k.htm
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C.
20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities and Exchange Act of 1934
Date of Report (Date of
earliest event
reported): June
14, 2010 (June 11, 2010) |
REGENERON PHARMACEUTICALS,
INC. |
(Exact name of registrant as
specified in its
charter) |
|
New York |
|
|
|
000-19034 |
|
|
|
13-3444607 |
|
(State or other
jurisdiction of |
|
(Commission File
Number) |
|
(I.R.S.
Employer |
incorporation) |
|
|
|
Identification
Number) |
777 Old Saw Mill River Road,
Tarrytown, New
York 10591-6707 |
(Address of principal executive
offices) (Zip
Code) |
|
|
(914) 347-7000 |
|
(Registrant's telephone
number, including area code) |
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of registrant under any of the
following provisions:
c |
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425) |
|
|
|
c |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12) |
|
|
|
c |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
c |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.07 |
|
Submission of Matters to a Vote of
Security Holders |
|
|
|
|
|
On June 11, 2010,
Regeneron Pharmaceuticals, Inc. held its Annual Meeting of Shareholders in
Tarrytown, New York. Shareholders voted on the matters set forth
below.
|
|
|
|
|
|
|
1. |
|
The nominees for election as Class I
Directors were elected, each for a three-year term expiring at the 2013
Annual Meeting of Shareholders. |
|
Nominee |
Votes For |
Votes Withheld |
Broker Non-Votes |
|
Leonard S. Schleifer |
82,881,842 |
2,612,770 |
7,375,225 |
|
Eric M.
Shooter |
82,825,682 |
2,668,930 |
7,375,225 |
|
George D. Yancopoulos |
82,879,911 |
2,614,701 |
7,375,225 |
|
|
|
2. |
|
The proposal to ratify the
appointment of PricewaterhouseCoopers, LLP as the Company’s independent
registered public accounting firm for the fiscal year ending December 31,
2010 was approved based upon the following
votes. |
|
Votes For |
91,869,117 |
|
|
Votes
Against |
468,375 |
|
|
Abstentions |
532,345 |
|
Pursuant to the requirements of the Securities and Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
REGENERON PHARMACEUTICALS, INC. |
|
|
Dated:
June 14, 2010 |
By: |
/s/ Stuart Kolinski |
|
|
|
|
Stuart
Kolinski |
|
|
Senior Vice President
and General Counsel |
2